Endless Biotech is Revolutionizing Tissue Culture Cultivation
Learn more about Early-Stage Shares
Accredited investor?
Get early access.
Limited time opportunity for EARLY STAGE INVESTORS to join our Regulation D offering through convertible notes, featuring early-stage investment discounts—25% below market value for investments of $25,000+, and a 50% discount for investments $250,000+. In the coming weeks, we anticipate our Regulation A+ $1.00 public stock offering qualification, paving the way for broader investor access. With a goal toward a NASDAQ IPO** in 2028, this is your chance to get in early and grow with us at the forefront of the agricultural biotech revolution.
To invest, you must meet at least one of the SEC’s criteria:
Endless Biotech is poised to revolutionize agriculture by integrating cutting-edge biotechnology with sustainable practices, aiming to enhance crop yields and resilience.
Chief Revenue Officer
Top Reasons to Invest in Endless Biotech
Visionary Growth
Pursuing a long-term strategy with the goal of a future NASDAQ IPO** and global expansion.
Fortune 100 Expertise
Led by seasoned executives with proven track records.
Early Stage Opportunity
Secure early-stage shares in a rapidly growing market.
Projected Global Cannabis Market by 2030
The global cannabis market is expected to hit $444 billion by 2030, fueled by legalization, innovation, and rising global demand.
SourceGlobal Agriculture Market by 2025
The global agriculture market is set to reach $15.5 trillion by 2025, driven by population growth, trade expansion, and tech innovation.
SourceMonthly Clone Production with Robotics & AI
Endless Biotech’s goal is to produce up to 5 million clones per month using robotics and AI—scaling agriculture with precision and consistency.
Strategic
Partners
Robotics &
AI Automation
- Consistency
- Efficiency
- Scalability
- Sustainability
Subscription Driven Eco System
Our subscription-based service offers a complete ecosystem for cultivators, providing them with regular shipments of tissue culture clones, expert advice, and cutting-edge growth solutions.
This model ensures that growers receive a steady supply of high-quality plants while benefiting from ongoing support, cost predictability, and scalability options to match their growth needs.
Data-Driven Solutions
We harness the power of data analytics and scientific insights to optimize every stage of cultivation. By continuously monitoring and refining our tissue culture processes, we ensure that growers receive plants with superior genetics and performance.
This data-driven approach allows us to predict growth patterns, enhance plant health, and deliver results that align with the evolving needs of the agriculture industry, ensuring maximum success for our partners.
Global Distribution
Endless Biotech is committed to serving cultivators on a global scale. With distribution networks established both nationally and internationally, we are positioned to deliver premium tissue culture plants to cultivators worldwide.
Our distribution strategy focuses on providing seamless, efficient access to our products, ensuring that our partners can rely on a consistent supply wherever they are located.
Endless Campus
As we look toward the future, our planned Endless Campus represents the heart of our innovation and growth. This state-of-the-art facility will serve as a hub for research, production, and collaboration, enabling us to scale operations while maintaining the highest standards of quality. The campus is a testament to our commitment to leading the agriculture industry into the future.
Proof of Concept
Initial Expansion
Scaling Up
Global Growth
Come See it Grow
We invite potential investors to visit our campus in Tulsa, Oklahoma, and see where the future of precision cultivation is being built. Tours are available Monday through Friday by appointment.
“Endless is defying the laws of Crop Steering Methodology. Their ability to produce phenomenal yields and high quality products is a cornerstone to their success. They are making a name for themselves locally, nationally, and internationally. It will be fun to watch them grow over the next few years!”
Regional Sales
Roadmap to 2029
Endless Biotech’s vision extends beyond today, with a strategic roadmap designed to drive the company’s growth through 2029. Our timeline includes expanding production capacities, entering new markets, and introducing breakthrough innovations in tissue culture technology. Each milestone brings us closer to becoming a global leader in cannabis cultivation and tissue culture solutions.
First 5 Million Tissue Culture Clones Delivered
Endless successfully hit a major milestone by delivering 5 million tissue culture clones to indoor and outdoor grow operations across the U.S.
Global Distribution Network Launched
Endless Biotech's international distribution network now reaches key markets worldwide, allowing the rapid deployment of tissue culture clones to growers globally.
First 5 Million Tissue Culture Clones Delivered
Endless successfully hit a major milestone by delivering 5 million tissue culture clones to indoor and outdoor grow operations across the U.S.
First 5 Million Tissue Culture Clones Delivered
Endless successfully hit a major milestone by delivering 5 million tissue culture clones to indoor and outdoor grow operations across the U.S.
Endless Plants
Horticulture
Advanced horticultural genetics ensuring improved yield, resilience, and consistency in everyday staples.
- Strawberry/Blueberry
- Banana
- Fig
- Potato
- Corn
Tree Species
Reliable, genetically optimized tree varieties for sustainable landscaping and agricultural applications.
- Paulownia (Empress tree)
- Ficus
Floriculture
Specialized floriculture genetics for vibrant and resilient blooms, including refined Orchids and robust Chrysanthemums (Mums).
- Mums
- Carnation
- Gerbera
- Orchids
Cannabis
Meticulously cultivated cannabis genetics engineered for optimal growth and unmatched potency.
- Indica
- Sativa
- Hybrid
Meet the Endless Biotech Team
Travis Dahm
A 15-year veteran of the financial and fintech industries, Travis has leveraged technology, entrepreneurial management, and client-focused strategies to scale companies into global enterprises.
Throughout his career, Travis has led international expansions across Asia, Europe, the Americas, and Australia, building multi-regional teams to support rapid growth. His expertise has helped businesses handle over $1 billion in payments annually, trillions in trade volume, and serve hundreds of thousands of clients.
Travis believes that a business thrives on strong teams and products. With a clear vision, the right team, and a superior product, success becomes a matter of seizing strategic opportunities and forming key partnerships.
David Hamilton
David Hamilton is a seasoned executive with a proven track record in scaling organizations and driving revenue growth across Fortune 100 and 500 companies, including HP, McKesson, and Philips Healthcare. Over his career, he has contributed to more than $250 billion in new revenue and brokered the largest tech deal in U.S. government history.
As a former CEO and current advisor to four Fortune 100s, David brings deep expertise across sales, operations, marketing, and investor relations. He’s known for leading transformative growth strategies grounded in trust, performance, and cross-functional integration.
David joins Endless Biotech with a bold vision: to help the company reshape the future of big agriculture and scale into a global market leader.
Tim Lozott
Leverages his experience as a vertical operator in the cannabis industry to position Endless Biotech as a global leader in tissue culture and clones. He joined the team to drive growth, scalability, and execute an exit strategy targeting a Nasdaq or NYSE listing by 2028.
Starting in corporate finance, Lozott managed REIT funds with $2–7 billion in real estate assets and holds expertise in finance, accounting, operations, and law. He transitioned into cannabis in 2018, leading a turnaround of a struggling pre-IPO company, increasing revenues, and orchestrating the $100 million sale of Acres Cannabis Las Vegas to Curaleaf.
Following this success, Lozott founded GreenLife Capital, a private equity firm that has raised over $300 million for cannabis and other ventures. He brings the experience needed to guide Endless Biotech to the public markets.
Braz Vaidya
Brajesh Vaidya is a pioneering figure in plant biotechnology, distinguished by his expertise in advancing tissue culture and plant propagation techniques that drive sustainable growth and commercial scalability in agriculture. With decades in the field, Braz has developed innovative protocols for creating disease-free plant stocks, critical in producing consistent, high-quality clones for commercial cultivation. His work emphasizes meticulous lab management, including developing and implementing SOPs that meet stringent regulatory standards, while optimizing efficiency for large-scale production environments.
Throughout his career, Braz has led teams in R&D, where his disciplined approach has facilitated substantial breakthroughs in plant tissue culture, viroid testing, and disease management. Braz excels in cross-functional collaboration, coordinating with both internal teams and external stakeholders to meet project timelines and deliver actionable insights that inform broader production strategies. Known for his ability to bridge scientific research with commercial application, he has helped build frameworks that streamline operations from pilot to full-scale production, making significant impacts on both national and international biotech initiatives.
Gary Holland
An engineer, director, and architect with extensive experience developing software for Fortune 500 companies and helping cannabis growers optimize operations. His blend of corporate insight and technical expertise allows him to craft effective solutions for complex challenges.
A U.S. Navy veteran, Gary served as a Nuclear Engineer on Ballistic Missile Submarines and developed a Nuclear Instrument Monitoring System still in use today. He also designed a patent-pending AI system modeled on human brain structures and contributed to NASA’s Next-Generation Shuttle Analysis Project.
Gary’s work in AI-based architectures has supported federal agencies and major corporations. His diverse education spans Computer Science, Astrophysics, Nuclear Engineering, and Electrical Engineering, giving him the tools to bridge cutting-edge technology with real-world business needs.
Courtney Bridges
Courtney Bridges is a scientist by day and an artist at heart, merging the precision of biology with the creativity of visual design. She earned a Bachelor of Science in Biology from the University of Maryland, where she focused on plant sciences and ecological systems. Alongside her scientific studies, she completed an Associate of Arts in Visual Design, giving her a unique ability to integrate analytical thinking with artistic expression.
Her career began at the USDA, where she gained invaluable experience in horticultural research, deepening her understanding of plant cultivation and environmental management. Simultaneously, her work in event space management refined her skills in operations, planning, and project coordination—abilities that would later support her entrepreneurial ventures.
Now, Courtney plays a key role in advancing horticultural research with Endless Biotech, applying her scientific expertise to explore innovative plant technologies. With a career rooted in science, design, and entrepreneurship, she continues to push boundaries in the medical plant industry.
“Endless Biotech is a cutting-edge, top-notch facility. Their team is dedicated, professional, and passionate, delivering exceptional data-driven results. If you want science-backed efficiency, Endless is the way to go.”
Regional Sales
Why invest in Endless Biotech early?
Early investment means high potential returns as the company grows.
Investing in Endless Biotech at this early stage gives you a chance to grow with a company that’s innovating in tissue culture, genetics, and automation. As these technologies scale, so does the potential for your investment to gain value.
With a goal of a NASDAQ IPO** by 2028, early shareholders are well-positioned to benefit from increased visibility and valuation. Being part of this foundational phase means securing a stake before broader market exposure drives demand.
What’s the growth plan from 2024 to 2028?
A clear path from first stock offering to Nasdaq listing.
Endless Biotech plans to complete its first SEC-qualified Reg A+ stock offering and launch initial fulfillment centers by the end of 2025. These foundational steps set the stage for expansion and operational capability.
By 2026, the company aims to open a 40,000-square-foot tissue culture lab, marking a major leap in biotech capacity. The roadmap includes a goal for a NASDAQ IPO** in 2028, positioning Endless as a global leader in cannabis biotechnology and innovation.
How does the cultivator subscription work?
Reliable, clean plants delivered on a schedule.
Endless Biotech offers a subscription service that delivers pathogen-free, tissue-culture-grown clones directly to cultivators. This ensures consistent plant quality and genetic stability, helping growers avoid the common pitfalls of traditional propagation.
With flexible delivery options and scalable plans, the service supports both small and large operations. It improves yield uniformity, simplifies compliance, and gives cultivators a dependable foundation for success.
How will Endless Biotech scale globally?
High-tech labs and smart partnerships fuel global expansion.
Endless Biotech is executing a multi-phase plan that includes building cutting-edge tissue culture facilities and setting up fulfillment centers on both U.S. coasts. Central to this is the development of the world’s largest cannabis tissue culture lab.
By integrating robotics, AI, and international partnerships, the company will expand into Northern Europe, Africa, and Asia. This strategy ensures localized support, faster delivery, and efficient global reach.
What is tissue culture, and why does it matter?
Clean, consistent plants with better yields.
Tissue culture is a modern method of plant propagation where cannabis is grown from tiny cell samples in a sterile lab environment. This guarantees each plant is disease-free and genetically identical to its source.
For cultivators, this means faster growth, uniform quality, and more predictable yields. It’s a powerful upgrade from traditional cloning, especially for scaling operations with precision and reliability.
Are tissue culture plants used for both medical and recreational cannabis?
Yes—purity and consistency benefit both markets.
Tissue culture plants are perfect for medical cannabis due to their purity, genetic consistency, and pathogen-free nature—key factors for patient safety and product reliability.
In the recreational space, the same traits ensure a uniform and high-quality consumer experience. This makes tissue culture a versatile solution for cultivators targeting both markets with confidence.
At Endless, we are combining data driven science, innovation using robotics and AI, and scale to deliver the next generation of cannabis cultivation. We’re not just growing plants—we’re building the future of agriculture. And with these existing and emerging technologies, the possibilities truly are Endless.
Chief Scientist, Head of Tissue Culture
Regulation A Tier 2 Stock Offering
- $1.00 per share
- Minimum 650 shares
- REG A+ "Regulation A" Stock Offering
- Pending Qualification